Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer—clinical aspects and relationship with tumour response: a single-centre prospective cohort studyMarie Kostine, Thierry Schaeverbeke, L. Rouxel et al.|Annals of the Rheumatic Diseases|2017Cited by 302
Vitiligo-like lesions occurring in patients receiving anti-programmed cell death–1 therapies are clinically and biologically distinct from vitiligoM. Larsabal, Julien Sénéschal, A. Marti et al.|Journal of the American Academy of Dermatology|2017Cited by 157
Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse eventsMarie Kostine, Thierry Schaeverbeke, Eleonora Mauric et al.|European Journal of Cancer|2021Cited by 93
Follow-Up of Patients With Complete Remission of Locally Advanced Basal Cell Carcinoma After Vismodegib Discontinuation: A Multicenter French Study of 116 PatientsF. Herms, Nicole Basset‐Séguin, Jérôme Lambert et al.|Journal of Clinical Oncology|2019Cited by 69
Trough dabrafenib plasma concentrations can predict occurrence of adverse events requiring dose reduction in metastatic melanomaMarine Rousset, Mathiéu Molimard, Caroline Dutriaux et al.|Clinica Chimica Acta|2017Cited by 36